A 150% Surge in IBD A First-in-Class Solution in Development
Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is projected to rise by 150% in Hong Kong between 2014 and 2034, with healthcare costs expected to exceed HK$400 million annually, according to an epidemiological study jointly led by The Chinese University of Hong Kong (CUHK)’s Faculty of Medicine (CU Medicine) and the University of Calgary.
The burden is growing. And the need for proactive resource allocation, early diagnosis, and scalable innovation has never been more urgent.
At MicroSigX, we’re developing a first-in-class, non-invasive microbiome-based diagnostic platform that detects IBD early, with high accuracy and at scale. Our proprietary technology delivers actionable insights before symptoms escalate, enabling earlier intervention, better outcomes, and a more sustainable healthcare future.
The need is urgent. The science is ready. The solution is in development.
We’re not watching the IBD crisis unfold—we’re engineering the way forward.
𝗠𝗶𝗰𝗿𝗼𝗦𝗶𝗴𝗫 – 𝗧𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺 𝗟𝗶𝘃𝗲𝘀 𝘄𝗶𝘁𝗵 𝗠𝗶𝗰𝗿𝗼𝗯𝗶𝗮𝗹 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀
https://lnkd.in/gV_aa3-c
#IBD
GenieBiome Limited 精進微生物科技有限公司
Microbiota I-Center (MagIC) (香港微生物菌群創新中心)
CUHK Medicine
